Exelixis

Exelixis Assets per Share

The Total Assets per Share of Exelixis (EXEL) as of Oct 31, 2026 is 10.09 USD. In the previous year, Total Assets per Share was 10.46 USD — a change of -3.50% (lower).

Assets per Share

10.09USD

YoY

-3.50%

Last updated:

Total Assets per Share of Exelixis is 2025 10.09 USD. Total Assets per Share of Exelixis was 2024 10.46 USD. It decreases by -3.50% lower compared to the previous year.

The Exelixis Assets per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Assets per Share
Date
Assets per Share
Jan 1, 2018
5.05 USD
Jan 1, 2019
6.69 USD
Jan 1, 2020
7.58 USD
Jan 1, 2021
9.28 USD
Jan 1, 2022
10.90 USD
Jan 1, 2023
10.44 USD
Jan 1, 2024
10.46 USD
Jan 1, 2025
10.09 USD
The Exelixis Assets per Share history
YEARAssets per ShareYoY
10.09USD-3.50%
10.46USD+0.18%
10.44USD-4.20%
10.90USD+17.40%
9.28USD+22.41%
7.58USD+13.35%
6.69USD+32.58%
5.05USD+117.05%
2.32USD+9.67%
2.12USD+79.80%
1.18USD+1.34%
1.16USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Exelixis Stock analysis

What does Exelixis do? Exelixis Inc. is a biopharmaceutical company that specializes in researching and developing drugs for various types of cancer. The company was founded in 1994 and is headquartered in Alameda, California. It has brought several drugs to the market over the years that have had a positive impact on thousands of patients. The company's founders, Corey Goodman, George Scangos, and John Walker, previously worked at Genentech and decided to start their own company to focus on cancer research and drug development. Exelixis Inc. has had numerous successes since its inception, including the development of Cabozantinib, a drug used to treat various types of cancer such as thyroid cancer, kidney cancer, and advanced prostate cancer. The company also has several drug candidates in clinical testing. Its business model revolves around researching and developing drugs that target proteins and signaling pathways overactivated in cancer cells. Exelixis Inc. often collaborates with other companies in the pharmaceutical industry to share development costs and risks. The company is divided into different divisions to treat various cancer types, including kidney, liver, thyroid, and lung cancer. One of its significant milestones was the approval of Cabozantinib by the FDA in 2012 for the treatment of advanced kidney and thyroid cancer. The drug has since been approved in other countries and has been successful in treating different types of cancer. Exelixis Inc. is dedicated to developing better and more effective cancer drugs to help patients. It works closely with doctors, researchers, and other pharmaceutical companies to constantly explore new approaches to combat cancer cells. In summary, Exelixis Inc. is a leading player in the research and development of drugs for various types of cancer. It has a track record of approved drugs and a pipeline of innovative drug candidates. The company's goal is to help cancer patients and contribute to improving people's health. Exelixis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Exelixis stock

Total Assets per Share of Exelixis is 10.09 USD in 2025.

Total Assets per Share of Exelixis changed from 10.46 USD to 10.09 USD, representing a -3.50% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Assets per Share Exelixis since 2006 – with annual values, charts, and detailed analysis.

Assets per share divides total assets by shares outstanding, indicating the total resource base backing each share of stock.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — Exelixis

All Key Metrics — Exelixis